With more than 90% of the biopharmaceutical industry made up of small, emerging companies, it is important for BIO to better understand early-stage investor and deal-making trends in order to determine where scientific or policy issues may be impacting the industry’s ability to maintain a robust pipeline of innovative medicines. The ability to access capital and form strategic alliances is vital for small therapeutic-focused companies to succeed in translating novel drug candidates into approved medical products for patients.
{iframe}http://go.bio.org/rs/490-EHZ-999/images/BIO%20Emerging%20Therapeutics%20Company%20Investment%20and%20Deal%20Trends%20Report%202008-2017.pdf?_ga=2.260367757.1080637402.1528137922-365835950.1504025860&utm_content=buffer4d718&utm_medium=social&utm_source=twitter.com&utm_campaign=bufferiab{/iframe}